Global Idiopathic Pulmonary Fibrosis (IPF) Market Opportunities and Forecast 2020-2027

  • DLR2864
  • 01 December, 2021
  • Pharma & Healthcare
  • Pages: 120
  • Global
Global Idiopathic Pulmonary Fibrosis (IPF) Market, By Medicine Type (Nintedanib, Pirfenidone, Other), By Mode of Application (Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other), By End User (Hospitals and Clinics, Other) and opportunities and forecast 2020-2027

Idiopathic Pulmonary Fibrosis (IPF) Market Overview

Increasing prevalence of idiopathic pulmonary pathology (IPF) and increasing geriatric population are the key drivers of the market. Rising range of cigarette smoking individuals, resulting in a high prevalence of IPF, is additionally projected to fuel the expansion.

Idiopathic pulmonary fibrosis (IPF) may be a rare, however serious respiratory organ disease. This ends up in a build-up of connective tissue within the lungs, that stiffens the lungs to Associate in Nursing extent wherever they are unable to expand and contract. Aging is taken into account because the greatest risk factor for development. Hence, period that the worldwide base of geriatric population is anticipated to grow over the forecast amount and is predicted to serve this market as a high impact rendering driver.

Report Metric Details
Market size available for years 2019–2027
Base year considered 2019
Forecast period 2020–2027
Forecast unit Value (USD Million)
Segments covered Medicine Type,Mode of Application,End User, and Region
Regions covered North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA)
Companies covered F. Hoffman La-Roche Ltd; Boehringer Ingelheim International GmbH; Galapagos;FibroGen, Inc.; Prometic Life Sciences Inc.;Bristol-Myers Squibb Company;MediciNova, Inc.;Merck & Co., Inc.;Novartis AG;Merck & Co.


The covid-19 Impact on Idiopathic Pulmonary Fibrosis (IPF) Market:

Like several different industries, COVID-19 badly knocked the electronic and semiconductor trade. This new event has compact nearly 230 countries in exactly a couple of weeks, leading to the forced conclusion of producing and transportation activities at intervals and across the countries. This has directly affected the expansion of the sector. It's calculable that COVID-19 to depart over USD thirty billion impacts on the physics and semiconductor trade. The arena is majorly affected thanks to transport restrictions on major physics and semiconductor staple suppliers. However, the rising want for semiconductors in many industries can supply fast market recovery over the longer-term amount.
 
Idiopathic Pulmonary Fibrosis (IPF) Market Segment Overview



By Medicine Type ,Nintedanib medicine type segment accounted major market share, Nintedanib and Esbriet (MAPK Inhibitor) by F. Hoffman La Roche and Ofev (Tyrosine enzyme Inhibitor) by Boehringer Ingelheim International GmbH square measure the sole drugs approved by the Food and Drug Administration (FDA) for the treatment of IPF ,each these medicine slow down the rate of useful decline in patients with IPF.
 
By Mode of Application,Antifibrotic Agent market segment accounted major market share .Moreover,IPF refers to a type of lung disease that causes scarring (fibrosis) of the lungs for an unknown reason. As time passes, this scarring gets worse and it becomes an to take in a deep breath and also the lungs cannot absorb enough oxygen. IPF may be a kind of opening lung an, principally involving the interstitium (the tissue and house interstitial air sacs of the lungs), and not directly involving the airways or blood vessels.
 
By  End User, Hospitals and clinics segment accounted huge market share,owing to prevalence of IPM diseases and increasing healthcare infrastructure is key factors to drive market of IPM market.
 
Market Analysis, Insights and Forecast – By Medicine Type
·       Nintedanib
·       Pirfenidone
·       Other

Market Analysis, Insights and Forecast – By Mode of Application
·       Antifibrotic Agents
·       Tyrosine Kinase Inhibitors
·       Other

Market Analysis, Insights and Forecast – By  End User
·       Hospitals and Clinics
·       Other

Idiopathic Pulmonary Fibrosis (IPF) Market Regional Overview

Region-wise, in terms of regions , North America led the IPF treatments market in 2018 attributable to high market penetration and increasing costs of the medication. The market is growing rapidly because of accelerated approvals of two medicine within the U.S. in 2014. Moreover, the increasing prevalence of IPF is one among the most important factors anticipated to spice up the market.

Idiopathic Pulmonary Fibrosis (IPF)-market, By Geography

·       North America (US & Canada)
·       Europe (UK, Germany, France, Italy, Spain, & Rest of Europe)
·       Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
·       LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
 
Idiopathic Pulmonary Fibrosis (IPF) Market Competitor overview

Some key developments and strategies adopted by manufacturers in the Idiopathic Pulmonary Fibrosis (IPF) are highlighted below.

·       In September 2017, F. Hoffman-La Roche Ltd declared positive results of a six-month study that combined Esbriet and Nintedanib. The study showed the same safety profile for the combination of 2 medicine to it expected for every drug alone.

Idiopathic Pulmonary Fibrosis (IPF) Market, Key Players -

·       F. Hoffman La-Roche Ltd;
·       Boehringer Ingelheim International GmbH;
·       Galapagos;
·       FibroGen, Inc.;
·       Prometic Life Sciences Inc.;
·       Bristol-Myers Squibb Company;
·       MediciNova, Inc.;
·       Merck & Co., Inc.;
·       Novartis AG;
·       Merck & Co.
 

Frequently Asked Questions (FAQ) :

Q1. What is the total CAGR expected to be recorded for the Idiopathic Pulmonary Fibrosis (IPF) market during the forecast period?

A. Idiopathic Pulmonary Fibrosis (IPF) market is expected to record a CAGR of ~ 9.8% during the forecast period.

Q2. Which segment is projected to hold the largest share in the Idiopathic Pulmonary Fibrosis (IPF) Market?

A. Antifibrotic Agents segment is projected to hold the largest share in the Idiopathic Pulmonary Fibrosis (IPF) Market.

Q3. What are the driving factors for the Idiopathic Pulmonary Fibrosis (IPF) market?

A. Increasing prevalence of idiopathic pulmonary fibrosis and rising hospital infrastructure ,these are main factors driving the growth of Idiopathic Pulmonary Fibrosis (IPF)market

Q4. Which Segments are covered in the Idiopathic Pulmonary Fibrosis (IPF) market report?

A. Medicine Type, Mode of Application, End User,and Region, these segments are covered in the Idiopathic Pulmonary Fibrosis (IPF) market report

Q5. Which are the prominent players offering Idiopathic Pulmonary Fibrosis (IPF)?

A. F. Hoffman La-Roche Ltd; Boehringer Ingelheim International GmbH; Galapagos;FibroGen, Inc.; Prometic Life Sciences Inc.;Bristol-Myers Squibb Company;MediciNova, Inc.;Merck & Co., Inc.;Novartis AG;Merck & Co.
Idiopathic Pulmonary Fibrosis (IPF) Market Study Global Market Analysis, Insights and Forecast, 2020-2027

    1. Introduction

    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Methodology
    • 1.4. Definitions and Assumptions

    2. Executive Summary

      3. Market Dynamics

      • 3.1. Market Drivers
      • 3.2. Market Restraints
      • 3.3. Market Opportunities

      4. Key Insights

      • 4.1. Key Emerging Trends – For Major Countries
      • 4.2. Latest Technological Advancement
      • 4.3. Regulatory Landscape
      • 4.4. Industry SWOT Analysis
      • 4.5. Porters Five Forces Analysis

      5. Global Idiopathic Pulmonary Fibrosis (IPF) Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 5.1. Key Findings / Summary
      • 5.2. Market Analysis, Insights and Forecast – By Medicine Type
        • 5.2.1. Nintedanib
        • 5.2.2. Pirfenidone
        • 5.2.3. Other
      • 5.3. Market Analysis, Insights and Forecast – By Mode of Application
        • 5.3.1. Antifibrotic Agents
        • 5.3.2. Tyrosine Kinase Inhibitors
        • 5.3.3. Other
      • 5.4. Market Analysis, Insights and Forecast – By End User
        • 5.4.1. Hospitals and Clinics
        • 5.4.2. Other
      • 5.5. Market Analysis, Insights and Forecast – By Region
        • 5.5.1. North America
        • 5.5.2. Europe
        • 5.5.3. Asia Pacific
        • 5.5.4. Latin America, Middle East, and Africa

      6. North America Idiopathic Pulmonary Fibrosis (IPF) Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 6.1. Key Findings / Summary
      • 6.2. Market Analysis, Insights and Forecast – By Medicine Type
        • 6.2.1. Nintedanib
        • 6.2.2. Pirfenidone
        • 6.2.3. Other
      • 6.3. Market Analysis, Insights and Forecast – By Mode of Application
        • 6.3.1. Antifibrotic Agents
        • 6.3.2. Tyrosine Kinase Inhibitors
        • 6.3.3. Other
      • 6.4. Market Analysis, Insights and Forecast – By End User
        • 6.4.1. Hospitals and Clinics
        • 6.4.2. Other
      • 6.5. Market Analysis, Insights and Forecast – By Country
        • 6.5.1. UK
        • 6.5.2. Germany
        • 6.5.3. France
        • 6.5.4. Italy
        • 6.5.5. Spain
        • 6.5.6. Russia
        • 6.5.7. Rest of Europe

      7. Asia Pacific Idiopathic Pulmonary Fibrosis (IPF) Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 7.1. Key Findings / Summary
      • 7.2. Market Analysis, Insights and Forecast – By Medicine Type
        • 7.2.1. Nintedanib
        • 7.2.2. Pirfenidone
        • 7.2.3. Other
      • 7.3. Market Analysis, Insights and Forecast – By Mode of Application
        • 7.3.1. Antifibrotic Agents
        • 7.3.2. Tyrosine Kinase Inhibitors
        • 7.3.3. Other
      • 7.4. Market Analysis, Insights and Forecast – By End User
        • 7.4.1. Hospitals and Clinics
        • 7.4.2. Other
      • 7.5. Market Analysis, Insights and Forecast – By Country
        • 7.5.1. China
        • 7.5.2. India
        • 7.5.3. Japan
        • 7.5.4. Australia
        • 7.5.5. South East Asia
        • 7.5.6. Rest of Asia Pacific

      8. Latin America, Middle East, and Africa Idiopathic Pulmonary Fibrosis (IPF) Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 8.1. Key Findings / Summary
      • 8.2. Market Analysis, Insights and Forecast – By Medicine Type
        • 8.2.1. Nintedanib
        • 8.2.2. Pirfenidone
        • 8.2.3. Other
      • 8.3. Market Analysis, Insights and Forecast – By Mode of Application
        • 8.3.1. Antifibrotic Agents
        • 8.3.2. Tyrosine Kinase Inhibitors
        • 8.3.3. Other
      • 8.4. Market Analysis, Insights and Forecast – By End User
        • 8.4.1. Hospitals and Clinics
        • 8.4.2. Other
      • 8.5. Market Analysis, Insights and Forecast – By Country
        • 8.5.1. Brazil
        • 8.5.2. Saudi Arabia
        • 8.5.3. UAE
        • 8.5.4. Rest of LAMEA

      9. Competitive Analysis

      • 9.1. Company Market Share Analysis, 2018
      • 9.2. Key Industry Developments
      • 9.3. Company Profile
      • 9.4. F. Hoffman La-Roche Ltd;
        • 9.4.1. Business Overview
        • 9.4.2. Segment 1 & Service Offering
        • 9.4.3. Overall Revenue
        • 9.4.4. Geographic Presence
        • 9.4.5. Recent Development
      *Similar details will be provided for the following companies
      • 9.5. Boehringer Ingelheim International GmbH;
      • 9.6. Galapagos;
      • 9.7. FibroGen, Inc.;
      • 9.8. Prometic Life Sciences Inc.;
      • 9.9. Bristol-Myers Squibb Company;
      • 9.10. MediciNova, Inc.;
      • 9.11. Merck & Co., Inc.;
      • 9.12. Novartis AG;

      Report You Might be Interested

      Choose License Type

      • USD
      • GBP
      • EURO
      • INR
      Credit card Logo

      Happy To Assist You

      Have a Question? email us at

      info@datalibraryresearch.com

      Or Call Us On

      US +1 360 851 1343

      IND +91 880 579 4934